Round Hill Asset Management Has $684,000 Stock Position in Bausch Health Companies Inc. (NYSE:BHC)

Round Hill Asset Management reduced its stake in Bausch Health Companies Inc. (NYSE:BHC) by 7.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 83,801 shares of the company’s stock after selling 6,774 shares during the quarter. Round Hill Asset Management’s holdings in Bausch Health Companies were worth $684,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Headlands Technologies LLC acquired a new stake in Bausch Health Companies during the 2nd quarter worth approximately $35,000. MQS Management LLC bought a new position in Bausch Health Companies during the 2nd quarter worth $71,000. Certuity LLC acquired a new stake in shares of Bausch Health Companies during the second quarter worth $75,000. Bfsg LLC boosted its position in shares of Bausch Health Companies by 46.7% in the second quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after acquiring an additional 3,643 shares during the period. Finally, Kendall Capital Management bought a new stake in shares of Bausch Health Companies in the second quarter valued at about $87,000. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Companies Stock Performance

Shares of BHC opened at $7.97 on Friday. Bausch Health Companies Inc. has a 52-week low of $3.96 and a 52-week high of $11.46. The firm has a market cap of $2.93 billion, a price-to-earnings ratio of -16.60 and a beta of 0.74. The business’s fifty day moving average is $8.37 and its 200-day moving average is $7.11.

Bausch Health Companies (NYSE:BHC) last released its earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.10. The firm had revenue of $2.51 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The business’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.03 earnings per share. As a group, research analysts forecast that Bausch Health Companies Inc. will post 3.74 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Evercore ISI upgraded shares of Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday, October 25th. Jefferies Financial Group reduced their price target on Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, August 7th. Scotiabank lowered their price objective on Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating on the stock in a research note on Friday, August 2nd. Finally, Royal Bank of Canada upped their target price on Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.75.

Insider Buying and Selling

In related news, EVP Seana Carson sold 13,370 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $6.21, for a total transaction of $83,027.70. Following the sale, the executive vice president now owns 435,198 shares of the company’s stock, valued at $2,702,579.58. This trade represents a 2.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 8.12% of the stock is owned by corporate insiders.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.